Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAM metallopeptidase with thrombospondin type 1 motif 8 is a secreted, extracellular enzyme of the ADAMTS protein family. It contains distinct functional domains: a metalloproteinase domain, disintegrin-like domain, and two thrombospondin type 1 motifs. The mature enzyme is generated by proteolytic processing of a precursor protein. ADAMTS8 negatively regulates angiogenesis and is implicated as a tumor suppressor based on its reduced expression profile in several types of human cancer, including lung neoplasms. It primarily functions through remodeling the extracellular matrix and regulating tissue responses such as cell proliferation. There are ongoing studies on its utility as a biomarker and potential therapeutic target, but selective drugs are not yet clinically available
If targeted pharmacologically, mechanisms would include inhibition of proteolytic activity (reducing angiogenesis and tumor microenvironment remodeling)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAM metallopeptidase with thrombospondin type 1 motif 8 (ADAMTS8).